. Author manuscript; available in PMC: 2020 May 18.

Published in final edited form as: Bone Marrow Transplant. 2019 Nov 18;55(5):906–917. doi: 10.1038/s41409-019-0748-1

Table 4.

Center characteristics associated with 100-day and 1-year overall survival on multivariable analysis

Characteristic	N		Odds Ratio^*^† (95% CI)	P-value
Characteristic	Patients	Centers	Odds Ratio^*^† (95% CI)	P-value

100-day survival
Center volume
≤ 40 alloHCT in 2010	1900	42	1
> 40 alloHCT in 2010	9637	41	1.41 (1.16–1.72)	<0.001

1-year survival
Center volume
≤ 40 alloHCT in 2010	1900	42	1
> 40 alloHCT in 2010	9637	41	1.32 (1.13–1.55)	<0.001
Long-term followup/survivorship program
No	5941	55	1
Yes	5596	28	1.23 (1.05–1.43)	0.009

Abbreviations: alloHCT – allogeneic hematopoietic cell transplantation; CI – confidence intervals

Odds ratio of being alive at 100-days or 1-year; odds ratio >1 indicates better odds of survival

^†

Adjusted for the following patient-level variables that were considered for risk-adjustment in the 2012 CIBMTR center-specific survival analysis: recipient age, recipient race/ethnicity, Karnofsky performance score at transplant, prior autologous transplant, recipient cytomegalovirus status, hematopoietic cell transplant comorbidity index score, disease stage, interval from diagnosis to transplant for acute myeloid leukemia and acute lymphoblastic leukemia, chemotherapy sensitivity for non-Hodgkin lymphoma and Hodgkin lymphoma, graft type, donor type HLA match, donor age for unrelated bone marrow or peripheral blood stem cell recipients, donor recipient sex match for bone marrow or peripheral blood stem cell recipients, conditioning regimen intensity for leukemia and year of transplant; transplant year was also included in the model for 100-day survival (additional information on variables included in the analysis is available at http://www.cibmtr.org/Meetings/Materials/CSOAForum/Pages/index.aspx)